Calls for papers
-
Aerosol testing company Proveris Scientific has announced two new appointments: Joseph Werbeck rejoins the company as Senior Director of Technical Service and Mohamed Eldam joins Proveris as Applications Chemist. Werbeck, who will report to VP… Read more . . .
-
AstraZeneca has announced that the first doses of its FluMist Quadrivalent live intranasal flu vaccine for the 2020-2021 US influenza season have shipped. FluMist Quadrivalent is approved for use in children over the age of… Read more . . .
-
TFF Pharmaceuticals announced that the company has raised $25.9 million in a private placement, with the funds to be used to “to accelerate the expansion of the company’s internal development portfolio beyond its programs for… Read more . . .
-
Biohaven Pharmaceutical will receive up to $250 million from Royalty Pharma on closing of a deal to fund development of its zavegepant (formerly vazegepant) calcitonin gene-related peptide (CGRP) receptor antagonist program, which includes intranasal zavegepant,… Read more . . .
-
An RA Capital Management company called Aerovate Therapeutics has raised $72.6 million in Series A financing for development of its AV-101 dry powder imatinib for the treatment of pulmonary arterial hypertension (PAH), the company said.… Read more . . .
-
Three weeks after recalling numerous lots of desmopressin nasal sprays in the UK and a number of other countries, Ferring has issued a recall of all lots of DDAVP 10 mcg/0.1ml, Stimate 1.5 mg/ml, and… Read more . . .
-
A Phase 3 trial of Levo Therapeutics’ LV-101 intranasal carbetocin in children with Prader-Willi Syndrome (PWS) failed to meet its primary endpoint, the company said. Enrollment in the study, which began in 2018, was stopped… Read more . . .
-
The FDA has cleared an IND for NeuroRx to conduct a clinical trial of an inhaled formulation of its RLF-100 aviptadil in patients with moderate or severe COVID-19, the company said. NeuroRx recently announced that… Read more . . .
-
Bryn Pharma said that it has raised $11 million in an extension of the financing that raised over $17 million in October 2019 to fund activities related to its BRYN-NDS1C epinephrine nasal spray candidate, which is… Read more . . .
-
Atossa Therapeutics said that it has gotten the go-ahead for a Phase 1 clinical study of its AT-301 nasal spray, which the company is developing for the treatment of COVID-19, and expects to begin enrollment… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA